Skip to main content

Our Mission

To improve the lives of people impacted by hypoparathyroidism through education, support, research, and advocacy. Learn more and get involved.


For U.S. patients receiving NATPARA through the Special Use Program

For a limited time the presentations can be viewed here on the website.

AZP-3601 is currently in development for the treatment of hypoparathyroidism

The study will be conducted at the National Institutes of Health.